A healthcare and physical AI company developing robotic systems for cardiovascular care and endovascular intervention
remedyrobotics.comLinkedInSan FranciscoMedtechFounded 2021
25 sources · checked 1 time, last 3d ago
The source says the round was led by DCVC, with participation from UC Investments, Skip Capital and Hostplus; it separately says existing backers Build Collective, Blackbird, Divergent Capital and KdT Ventures also participated.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $62M | 2026-11-09 | DCVC | No recent discussion |
25 sources · checked 1 time, last 3d ago [ VERIFIED · CORRECTED ] read against 1 of 25 sources
The source says the round was led by DCVC, with participation from UC Investments, Skip Capital and Hostplus; it separately says existing backers Build Collective, Blackbird, Divergent Capital and KdT Ventures also participated. | ||||
Remedy Robotics builds the N1, an AI-enabled robotic system that lets specialist clinicians perform complete endovascular procedures on-site or remotely for patients with stroke and other cardiovascular emergencies.
Remedy says endovascular intervention is the gold-standard treatment for stroke and other cardiovascular emergencies, but only 2.8% of eligible stroke patients worldwide have access, making geography and specialist shortages consequential. After completing the world's first fully remote neurointerventional procedures in humans and reporting work with more than 100 hospitals, the company raised $62 million in Series B funding led by DCVC to support a University of California pivotal trial, FDA progress, prototype deployment, and further autonomy.
Checked against 10 sources 3d ago
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Seed and Series A | $35 million | 2025-10-06 | DCVC | |